Clinical Trial Update: Dual Administration Of Intraperitoneal And Intravenous TROP2-Directed CAR-NK With TGF-Beta Receptor 2 (TGFBR2) Knock Out (KO) Therapy For Colorectal Cancer-Related Peritoneal Carcinomatosis: A Phase 1/2 Trial ("Chip-CRC Trial") [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating dual intraperitoneal and intravenous TROP2-directed CAR-NK cells with TGFBR2 knockout for colorectal cancer-related perito…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer
• Peritoneal Carcinomatosis

Drugs mentioned

• TROP2-directed CAR-NK therapy with TGFBR2 knockout (CAR-NK cell therapy targeting TROP2 with TGFBR2 knockout)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Colorectal Cancer, Peritoneal Metastases | Phase 1, Phase 2 | Status: RECRUITING